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Abstract: Patients with primary intrinsic brain tumors can experience neurological, cognitive, 
and psychiatric symptoms that greatly affect daily life. In this review, we focus on changes in 
personality and behavior, mood issues, hallucinations, and psychosis, because these are either 
difficult to recognize, to treat, or are understudied in scientific literature. Neurobehavioral 
symptoms are common, often multiple, and causation can be multifactorial. Although different 
symptoms sometimes require a different treatment approach, we advise a comprehensive treat-
ment approach, including pharmacological treatment and/or psychotherapy where appropriate. 
Further research is needed to obtain a better estimate of the prevalence of psychiatric symptoms 
in glioma patients, and the extent to which these affect everyday functioning and family life.
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Background
Gliomas (World Health Organization [WHO] grade II, III, or IV) are the most common 
primary malignant brain tumors, with an incidence of six per 100,000.1 Despite efforts 
in improving the treatment of gliomas, these tumors cannot be cured. Patients suffer-
ing from a low-grade glioma (WHO grade II) have a median survival of 5–15 years,2 
while this is 2–3 years for patients with a WHO grade III tumor.3,4 For patients with 
WHO grade IV tumors, the median survival does not exceed 12–14 months.5 While 
survival is traditionally stratified by tumor grade, genetic markers including IDH muta-
tion, 1p/19q codeletion, and MGMT methylation have more recently been established 
as important prognostic markers in glioma patients.6 The antitumor treatment usually 
consists of a combination of surgery, radiotherapy, and chemotherapy. In addition, 
drugs for symptom management, such as corticosteroids and anticonvulsants are often 
prescribed for a prolonged period of time.7,8
As the tumor progresses, various symptoms resulting from the disease often become 
more pronounced. As both the disease and its treatment have a direct effect on brain 
functioning, patients commonly experience neurological, cognitive, and psychiatric 
symptoms.9 Neurobehavioral symptoms may affect the patient’s ability to engage 
with clinical decision-making and ultimately may affect survival. Moreover, these 
symptoms can negatively affect patients’ direct social environment, such as spouses, 
family members, and close friends.10 With the patients’ increasing demand for men-
tal and physical support, these significant others often become informal caregivers. 
Because of the substantial impact of the disease and its treatment on the everyday lives 
of patients and their loved ones, it is important to pay attention to symptom manage-
ment and quality of life. Changes in personality and behavior, mood issues, hallucina-
tions, and psychosis are either difficult to recognize, to treat, or are understudied in 
scientific literature. In this review, we will therefore focus on these neurobehavioral 
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symptoms. Different treatment options are summarized and 
presented in Table 1.
Changes in personality and behavior
Most studies focusing on changes in personality and behav-
ior in brain tumor patients use a qualitative study approach, 
or are case reports. An estimation of the real frequency of 
behavioral problems experienced by glioma patients and 
their informal caregivers is uncertain, but these qualitative 
studies allow for a detailed description of commonly expe-
rienced issues.
Symptoms of anger, loss of emotional control, indiffer-
ence, and change in behavior are commonly reported.11–15 
Changes in personality can lead to difficulties recognizing 
and interpreting social behavior. Such difficulties in social 
cognition can interfere severely with family life and social 
relationships. For other brain tumor patients, personality 
changes can manifest as exhaustion and anxiety, leading to 
withdrawal from social situations, and feelings of sadness and 
grief.14 These changes may, as in any cancer patient faced 
with a dismal prognosis or uncertainty concerning the future, 
in part be explained or compounded by processes of grief 
or an adjustment disorder. However, personality changes 
can also result directly from the presence of the tumor or its 
treatment. The precise extent to which tumor location impacts 
on psychopathology is not well understood.
Classically, three “frontal lobe syndromes” have been 
proposed to arise in patients with brain tumors located in 
specific prefrontal areas.16 In this model, damage to dorso-
lateral prefrontal areas is associated with impaired executive 
functioning, orbitofrontal damage may cause disinhibition 
and impulsiveness, and lesions in the medial frontal areas 
may result in apathy or abulia.17,18 It is worth acknowledg-
ing that this broad model is underpinned by relatively little 
recent, high-quality evidence that is specific to brain tumor 
patients. Brain tumor-specific studies may be important, 
given the considerable uncertainty over how tumor-related 
metabolic changes, diaschisis, and cerebral edema or mass 
effect may interact with location to mediate the behavioral 
phenotype.
A few quantitative studies do indicate that behavioral 
problems are more evident in patients with frontal tumors 
than in controls without neurological compromise.19 Patients 
with frontal tumors report more executive dysfunction, 
apathy, and disinhibition than patients with nonfrontal 
tumors.20 However, clinically significant levels of apathy 
and executive dysfunction are reported by many patients 
with tumors located outside the frontal lobes too, and the 
relationship is not straightforward.20 Indeed, it is likely that 
highly complex interactions between cortical and subcortical 
damage adds to behavioral problems. For example, patients 
with heteromodal frontal or parietal tumors often experi-
ence negative mood states. When paralimbic structures are 
involved, mood problems become more aggravated. How-
ever, damage to motor and somatosensory cortex is associ-
ated with positive mood and seems to ameliorate negative 
mood states.21 It therefore seems unlikely that behavioral 
problems are a direct result of frontal or nonfrontal damage. 
One recent study using voxel-based lesion−symptom map-
ping (VLSM) provides some interesting evidence for more 
subtle neuropsychological effects of tumor location. The 
ability to discern the emotions and intentions of others was 
Table 1 Treatment options for changes in personality and behavior, mood issues, and hallucinations and psychosis in patients with glioma
Treatment options
Changes in personality and behavior Mood issues Hallucinations and psychosis
Psychological treatment:  
psychoeducation; cognitive behavioral  
therapy; coping enhancement
Pharmacological treatment:
antidepressants; anxiolytics
Reduction or cessation of medications  
that may cause the hallucinations and/or 
psychosis
Neurorehabilitation High-intensity psychological treatment:  
cognitive behavioral therapy; interpersonal therapy
Pharmacological treatment: 
antipsychotics
Alternative approach:
problem-solving therapy; mindfulness; exercise  
intervention; nurse-delivered supportive  
intervention
Supportive care:
familiar nursing; regular reassurance;  
de-escalation and reorientation
Psychological treatment:
cognitive behavioral therapy; coping  
enhancement
Alternative approach:
acceptance and commitment therapy;  
mindfulness
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impaired in patients with tumors in the temporal lobe. More 
complex components of personality and behavior (such as 
the ability to conceptualize and describe internal emotions 
and the facets of one’s character) were adversely affected 
by tumors in prefrontal regions.22 The advent of more sensi-
tive neuroimaging and analysis techniques such as VLSM 
brings the opportunity to explore the relationship between 
tumor location and psychopathology in greater detail than 
was previously possible.
Many patients have only limited awareness of their 
symptoms. Impaired emotion recognition and behavioral 
problems are associated with a lack of self-awareness, which 
can lead to perspective-taking difficulties. After surgery, 
brain tumor patients are more likely to underestimate their 
psychological problems and the negative impact of changes 
to their emotional functioning, interpersonal relationships, 
neurocognitive functioning, and coping skills.23 This can be 
distressing for partners and others who are closely involved.23 
Moreover, lack of awareness of deficits can have a major 
impact on the outcome of rehabilitation after treatment.24 
As social and behavioral problems are often very difficult to 
detect in clinical neuro-oncological practice, but can affect 
the lives of patients and their partners in a very profound 
way, these issues are of special concern.
Managing changes in personality  
and behavior
Recently, Chambers et al published a comprehensive over-
view of guidelines for psychosocial care in neuro-oncology.25 
In terms of management of changes in personality and behav-
ior, the authors advise patient education, early detection of 
symptoms, and referral to neuropsychology, neuropsychiatry, 
or neurorehabilitation services if needed.25
To encourage early detection of symptoms, health care 
professionals should enquire after behavioral problems in 
routine consultation. While patients may not be aware of 
problems in everyday life, the informal caregivers can usu-
ally indicate if behavioral changes cause issues. Although 
to our knowledge, there are no brain tumor-specific, 
validated paper-and-pencil screening instruments avail-
able to assess changes in behavior, a question such as the 
personality change item of the Functional Assessment of 
Cancer Therapy-Brain26 (“I am bothered by the change in 
my personality”, with answer options ranging from “not at 
all” to “very much”) may suffice in determining whether 
patients should be referred for extensive psychological 
assessment. Neuropsychological testing is then warranted 
to assess different aspects of the patients’ social cognition. 
However, development of screening instruments and valida-
tion of existing, more comprehensive questionnaires such as 
the Neuropsychology Behavior and Affect Profile27 and the 
Katz Adjustment Scale-Revised28 in the brain tumor patient 
population would be worthwhile.
To help patients and their informal caregivers cope with 
changes in personality and behavior, it is important to pro-
vide education. Improved education can reduce uncertainty 
and distress, and increase empowerment.29,30 In a recent 
systematic review, Langbecker and Janda investigated the 
available interventions to improve information provision 
for brain tumor patients and their informal caregivers.31 
They conclude that although satisfaction rates of patients 
and their informal caregivers improve when an intervention 
is offered, more research is needed to determine the most 
effective intervention components and the most appropriate 
timing for the delivery of the intervention.
In usual practice, the focus is mostly on the physical 
recovery of the patient,32 but improvements in neurocognitive 
functioning are sometimes evaluated as well through brief 
screening measures such as the functional independence 
measure (FIM).33–37 Some evaluation studies show mod-
est improvement in brain tumor patients’ social cognition 
(assessed with the FIM as social interaction, problem-solving, 
and memory38), which does not appear to be related to the 
tumor type.35,36,39 However, it remains unclear whether the 
very brief FIM cognitive scores adequately reflect more 
subtle behavioral and personality changes and difficulties in 
social functioning in everyday life. Moreover, only inpatient 
groups were studied, which hinders the generalization of find-
ings – especially with respect to patients with less malignant 
tumor such as low-grade gliomas. More prospective studies 
and randomized controlled trials (RCTs) to evaluate the role 
of neurorehabilitation in improving social functioning are 
therefore warranted.
Psychologists can support patients and informal care-
givers to employ more effective coping strategies to deal 
with changes in personality and behavior.40 Alternatively, 
an adapted cognitive behavioral approach could be used. 
Defining the changed personality as the end behavior, an 
assessment can formulate an understanding of the patient’s 
thoughts and emotions, and where these might interact to 
cause the problematic behavior. With this approach, it may 
become possible to identify possible targets for therapeu-
tic intervention. However, there are, to our knowledge, 
no intervention programs available aimed specifically at 
glioma patients’ difficulties with changes in behavior and 
personality. Although (neuro) psychologists aware of the 
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disease-specific symptoms of brain tumors may effectively 
apply the principles of cognitive behavioral therapy (CBT), 
further studies are also warranted here.
Mood issues
Following the diagnosis of glioma, many patients experi-
ence psychological distress and mood issues. Mania, feel-
ings of anxiety, depression, and even suicidal ideation can 
occur. Furthermore, shock and disbelief, anger and despair, 
dysphoria and anxiety, or intrusive thoughts about the 
disease may be prominent.41 Often, these emotional reac-
tions are transient in nature, but sometimes their severity 
and/or persistence suggests an adjustment disorder or a 
major depressive disorder.42 Moreover, mania and other 
mood disorders may in rare cases occur secondary to the 
brain lesion itself,43 although the underlying mechanisms 
are not well understood.44,45 Therefore, a biopsychosocial 
framework, taking into account the dynamic interactions 
between neurocognitive factors, psychological processes, 
and the social environment has been suggested as useful 
to conceptualizing these disorders.46 For example, patients 
with a personal or family history in psychiatric disease are 
more susceptible to psychological maladjustment after brain 
tumor.47,48 Moreover, mood issues can be attributed variously 
to side effects of treatment (eg, antiepileptics49), biochemical 
changes in the brain,45 changes in cytokine levels,50 elevated 
intracranial pressure, or the location of the tumor.51 Frontal 
cortex lesions and lesions in the parietal association cortex 
and paralimbic structures have been associated with mood 
changes, specifically.21 Demographic variables such as sex, 
age, marital status, ethnicity, and education level are not 
consistently associated with anxiety and depression in glioma 
patients, but increased physical disability and cognitive 
impairment often co-occur with mood issues.52
Systematic reviews and longitudinal studies suggest that 
approximately 15%–20% of glioma patients will develop 
clinical major depressive symptoms during the first 8 months 
after diagnosis.52,53 In this, no clear distinction between low- 
and high-grade gliomas can be made based on the available 
literature.52 The increased risk for depression may be main-
tained up to a year after surgical intervention.54 This makes 
depression considerably more likely than in the general popu-
lation (where the point prevalence is approximately 5%).55 
However, there is no consistent evidence that brain tumor 
patients are at a higher risk of depression than patients with 
cancer not involving the central nervous system.48,56
To date, very little research has been performed to 
examine the prevalence of suicidal ideation among brain 
tumor patients. In a large retrospective study among adult 
survivors of a childhood brain tumor, approximately 12% 
of patients experienced suicidal ideation.57 In this study, 
depression, psychoactive medication use, history of seizures, 
and observation or surgical treatment were associated with 
suicidal ideation. With regard to successful suicide, there are 
indications that brain tumor patients are at an increased risk 
for death by suicide.58,59 However, others have reported that 
patients with brain tumors are less likely to commit suicide 
than other patients with cancer,60 and are more likely to die 
an accidental death instead.61 Nevertheless, the use of gluco-
corticoids such as dexamethasone, which is often prescribed 
in glioma patients, increases the risk for suicide or suicide 
attempt, depression, and panic disorder considerably.62 From 
the epilepsy literature, we know that suicidal thoughts can 
co-occur after temporal lobe surgery.63
It is a commonly acknowledged problem that mood 
issues, when understandable given the disease stage or pro-
cess, can be difficult to discuss for health care professionals.64 
In neuro-oncology, this likely not only pertains to under-
standable psychological reactions, but also to what can be 
expected based on the tumor type, location, and treatment 
side effects.65 Mood issues that are potentially treatable may 
then be overlooked and undertreated.66 This can have serious 
negative consequences for glioma patients’ quality of life,67 
and even their morbidity and survival.47,68
Managing mood issues
As mentioned above, recognizing mood issues may be 
difficult in the glioma patient population. When it is sus-
pected, either from the patient’s perspective or the informal 
caregiver’s point of view, that mood issues interfere with 
everyday functioning, clinical assessment is needed to diag-
nose or exclude mood disorders. While it remains necessary 
to conduct a thorough psychiatric assessment to assess the 
degree of mood issues, there are screening measures that 
could be useful in the clinic. Recently, efforts have been 
made to validate three of these instruments in the glioma 
patient population.69 The Hospital Anxiety and Depres-
sion Scale70 and the Patient Health Questionnaire-971 can 
be useful to screen for mood issues. The Beck Depression 
Inventory-II72 is also often used in clinical practice but has 
not yet been validated in glioma patients. However, the util-
ity of any screening scale for mood issues in glioma patients 
with significant cognitive impairment, or in patients in the 
palliative phase, is currently unknown.
National and international guidelines suggest that depres-
sion in patients with a chronic physical condition should, 
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where possible, be treated with a combination of medica-
tion (eg, selective serotonin reuptake inhibitors [SSRIs], 
serotonin norepinephrine reuptake inhibitors, anxiolytics), 
and a high-intensity psychological treatment such as CBT 
or interpersonal therapy.73,74 Generally, pharmacological 
treatment and psychotherapeutic treatment are thought to 
contribute equally to beneficial effects.75
A lack of RCTs in glioma patients makes it difficult to 
gauge whether the same treatment strategies should be pur-
sued in patients with brain tumor.76 Glioma patients are at a 
high risk of cognitive deficit and fatigue and may struggle 
to fully benefit from CBT. Antidepressant treatment brings 
the possibility of adverse drug interactions, for example, an 
increased risk of antiepileptic drug (AED) toxicity second-
ary to inhibition of metabolizing liver enzymes. Although 
antidepressants generally do not trigger epilepsy in healthy 
individuals, their risk of precipitating seizures in patients 
with a tumor growing in their brain is unknown. Regardless, 
both physicians and patients may at times be reluctant to 
initiate new pharmaceutical treatment.77 RCTs are therefore 
warranted to investigate the effectiveness of the standard 
treatment for mood disorders. Some retrospective evidence 
suggests that SSRIs may be well tolerated by patients with 
glioblastoma but more research is clearly required.78
Other initiatives should not be overlooked. Presently, 
we are conducting an RCT to evaluate the effects of an 
internet-based guided self-help course on depressive 
symptoms in glioma patients.79 Other interventions that are 
already evidence-based in other patient populations include 
problem-solving therapy80 and mindfulness.81,82 Moreover, 
interventions based on exercise programs appear to have a 
positive impact on both mood and the quality of life,83 and 
nurse-delivered interventions based on information provision 
and supportive attention show beneficial effects on mood in 
newly diagnosed cancer patients.84 Adapting existing and 
effective interventions to the glioma patient situation, by 
taking their disease-specific symptoms into account, could 
lead to improved evidence-based care for mood issues in 
glioma patients.
Hallucinations and psychosis
Although rare, some brain tumors present themselves 
through neurobehavioral or psychiatric symptoms only.85 
Hallucinations16 and even psychosis86 have been reported in 
brain tumor patients. These symptoms can be very unsettling 
to patients and their informal caregivers. Currently, there is 
no evidence of a causative relationship between classical 
paranoid schizophrenia and brain tumors. Although large 
studies are lacking, there are indications that idiosyncratic 
psychoses can occur after resection of the (mesial) tempo-
ral lobes. Case studies describe acute psychosis, agitation, 
and suicidal/homicidal ideations with paranoia following 
surgery.86
Indeed, most studies of hallucinations and psychosis 
in glioma patients are case reports. As case reports often 
feature highly complex cases, with glioma patients who are 
suffering not only from the tumor, but also from epilepsy that 
is difficult to treat, psychosis, behavioral problems, and/or 
suicidal ideation,63,87,88 it is very difficult to make general 
statements about the prevalence of these symptoms in glioma 
patients per se. A review of case studies found that 22% of 
148 cases experienced psychotic symptoms (here defined as 
delusions or hallucinations).89
Psychiatric symptoms seldom occur in isolation from other 
(psychiatric) symptoms in patients with brain tumors, eg, as 
shown in a study by Sokolski and Denson.90 Hallucinations in 
any sensory modality may occur as an epileptic phenomenon. 
In such cases, the hallucinations may subside after effective 
AED treatment, or surgical removal of the tumor.91 In addi-
tion, associations have been found between epilepsy and mood 
disorders. For example, manic or hypomanic states have been 
reported in patients undergoing temporal lobectomy for epi-
lepsy, and postoperative mood disorders seem to be associated 
with preoperative postictal psychosis.92 Although psychosis 
appears to be more common in patients with temporal lobe 
epilepsy (~5%–15% of patients)93 than in brain tumor patients, 
it can occur and can have a major impact on people’s lives.
Managing hallucinations and psychosis
It is important to obtain a clear view of the patients’ hallu-
cinations, and/or psychotic symptoms. In general, patients 
are able to describe their hallucinations if prompted. Hal-
lucinations suggestive of an organic cause, such as brain 
tumor, are often visual, and auditory hallucinations tend to 
be nonpersecutory in nature.
Treatment of hallucinations usually consists of pharma-
cological treatment (eg, antipsychotics).94 Olanzapine or 
risperidone for example have been shown to counteract hallu-
cinations.95 However, it is unclear how well these drugs work 
to reduce unimodal hallucinations not accompanied by other 
psychiatric symptoms, but mainly resulting directly from the 
lesion. On the other hand, hallucinations and psychosis often 
co-occur with other psychiatric symptoms.90 This is important 
to note, as the treatment used for the management of other 
symptoms can have an adverse effect on hallucinations and 
psychosis, and vice versa. For example, the use of steroids 
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or AEDs can induce psychosis in brain tumor patients.96 
Steroid psychosis generally arises at or shortly after the onset 
of corticosteroid treatment, and a higher dose increases the 
risk. The psychosis is characteristically, but not inevitably, 
affective and may fluctuate. Furthermore, although rare, 
antidepressants (SSRIs) may evoke hallucinations, which 
generally subside after cessation of medication.97 In close col-
laboration with the treating neuro-oncology team, reduction 
or cessation of medications that may cause the hallucinations 
and/or psychosis can be indicated. Alternatively, a regular 
low-dose antipsychotic such as haloperidol can be useful.
As hallucinations and psychotic symptoms can be very 
unsettling for both patients and their significant others, a 
nonpharmacological approach can prove beneficial as well. 
To reduce anxiety and disorientation, nursing provided by a 
familiar face, regular reassurance, de-escalation, and reori-
entation can provide relief. Other options include CBT for 
psychosis,98 or a combination with coping enhancement such 
as hallucination-focused integrative therapy, which has been 
shown to improve the quality of life.99 Mindfulness-based 
interventions100 and acceptance and commitment therapy101 
for treating the emotional problems that may follow a 
psychotic episode have also been investigated, and show 
promising results. For auditory hallucinations specifically, 
Thomas et al recently provided a rather complete overview of 
the recent developments in treatment, including RCTs focus-
ing on different types of CBT, and avatar therapy.102 Here, 
computer-generated avatars allow the patient to role-play 
with different responses to their auditory hallucination.
Conclusion
Neurobehavioral symptoms are common in brain tumor 
patients, often occur concurrently, and are difficult to tell 
apart. For example, affective disorders can co-occur with or 
mirror alexithymia,103 fatigue, and apathy, whereas a different 
approach in treatment may be necessary. Symptoms should 
preferably not be treated separately, but comprehensively. 
Depending on the severity of symptoms, pharmacological 
treatment and/or psychotherapy may be advisable. Therapists 
supporting brain tumor patients should always have thorough 
knowledge of the disease-specific symptoms of brain tumors 
to adequately address patients’ and informal caregivers’ 
needs. More research is needed to obtain a better estimate 
of the prevalence of the different psychiatric symptoms in 
glioma patients, and the extent to which these affect everyday 
functioning and family life.
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